PBB3 binding in a patient with corticobasal syndrome

Pérez‐Soriano, Alexandra; Matarazzo, Michele; Vafai, Nasim; Shahinfard, Elham; Miao, Qing; Higuchi, Makoto; Stoessl, A. Jon

doi:10.1002/mds.27405

Cited by 7 publications

(5 citation statements)

References 8 publications

(8 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…18 F‐AV1451 and 11 C‐PBB3 PET showed high uptake in the affected regions in CBS, but 18 F‐AV1451 showed difficulty in detecting the deposits of 4‐repeat tau using autoradiography and has off‐target binding to several molecules, such as monoamine oxidase A and neuromelanin , which are not related to tau pathology. 11 C‐PBB3 PET studies have been conducted in only single cases , and possible off‐target binding of 11 C‐PBB3 remains unclear. On the other hand, it is widely considered that the off‐target binding of 18 F‐THK5351 results from the alternative binding to MAO‐B .…”

Section: Discussionmentioning

confidence: 98%

“…Another possibility is that any changes in 18 F-THK5351 retention are masked by 18 F-THK5351 binding to physiological MAO-B-containing cells in these brain areas [9]. 18 F-AV1451 [5][6][7] and 11 C-PBB3 [3,12] PET showed high uptake in the affected regions in CBS, but 18 F-AV1451 showed difficulty in detecting the deposits of 4-repeat tau using autoradiography [13][14][15] and has off-target binding to several molecules, such as monoamine oxidase A [16] and neuromelanin [17], which are not related to tau pathology. 11 C-PBB3 PET studies have been conducted in only single cases [3,12], and possible off-target binding of 11 C-PBB3 remains unclear.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Longitudinal changes in ¹⁸F‐THK5351 positron emission tomography in corticobasal syndrome

Ezura

Kikuchi

Ishiki

et al. 2019

Euro J of Neurology

View full text Add to dashboard Cite

Background and purpose Corticobasal syndrome (CBS) is pathologically characterized by tau deposits in neuronal and glial cells and by reactive astrogliosis. In several neurodegenerative disorders, 18F‐THK5351 has been observed to bind to reactive astrocytes expressing monoamine oxidase B. In this study, the aim was to investigate the progression of disease‐related pathology in the brains of patients with CBS using positron emission tomography with 18F‐THK5351. Methods Baseline and 1‐year follow‐up imaging were acquired using magnetic resonance imaging and positron emission tomography with 18F‐THK5351 in 10 subjects: five patients with CBS and five age‐matched normal controls (NCs). Results The 1‐year follow‐up scan images revealed that 18F‐THK5351 retention had significantly increased in the superior parietal gyrus of the patients with CBS compared with the NCs. The median increases in 18F‐THK5351 accumulation in the patients with CBS were 6.53% in the superior parietal gyrus, 4.34% in the precentral gyrus and 4.33% in the postcentral gyrus. In contrast, there was no significant increase in the regional 18F‐THK5351 retention in the NCs. Conclusions Longitudinal increases in 18F‐THK5351 binding can be detected over a short interval in the cortical sites of patients with CBS. A monoamine oxidase B binding radiotracer could be useful in monitoring the progression of astrogliosis in CBS.

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

Longitudinal changes in ¹⁸F‐THK5351 positron emission tomography in corticobasal syndrome

Ezura

Kikuchi

Ishiki

et al. 2019

Euro J of Neurology

View full text Add to dashboard Cite

show abstract

“…To the best of our knowledge, no study has yet attempted to assess the accuracy of PBB3, although the evidence so far imply a good accuracy for discrimination of HCs and clinically diagnosed AD patients and a different regional pattern of binding for non-AD neurodegenerative diseases [27,[47][48][49][50][51][52].…”

Section: Phase 2: Clinical Assay Development For Alzheimer's Disease Pathologymentioning

confidence: 99%

Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework

Chiotis

Dodich

Boccardi

et al. 2021

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Purpose The research community has focused on defining reliable biomarkers for the early detection of the pathological hallmarks of Alzheimer’s disease (AD). In 2017, the Geneva AD Biomarker Roadmap initiative adapted the framework for the systematic validation of oncological biomarkers to AD, with the aim to accelerate their development and implementation in clinical practice. The aim of this work was to assess the validation status of tau PET ligands of the THK family and PBB3 as imaging biomarkers for AD, based on the Biomarker Roadmap methodology. Methods A panel of experts in AD biomarkers convened in November 2019 at a 2-day workshop in Geneva. The level of clinical validity of tau PET ligands of the THK family and PBB3 was assessed based on the 5-phase development framework before the meeting and discussed during the workshop. Results PET radioligands of the THK family discriminate well between healthy controls and patients with AD dementia (phase 2; partly achieved) and recent evidence suggests an accurate diagnostic accuracy at the mild cognitive impairment (MCI) stage of the disease (phase 3; partly achieved). The phases 2 and 3 were considered not achieved for PBB3 since no evidence exists about the ligand’s diagnostic accuracy. Preliminary evidence exists about the secondary aims of each phase for all ligands. Conclusion Much work remains for completing the aims of phases 2 and 3 and replicating the available evidence. However, it is unlikely that the validation process for these tracers will be completed, given the presence of off-target binding and the development of second-generation tracers with improved binding and pharmacokinetic properties.

show abstract

“…A multimodal case revealed however that 18 F-AV-1451-PET imaging correlates with 4R-tau pathology (38). An interesting observation was made in the context of 11 C- PBB3-PET in the examination of CBS (39). Examination using 11 C- PBB3-PET revealed asymmetric affinity of the radiotracer, greater on the right, in the frontal, temporal, parietal, and occipital cortex (39) Analogical changes were also observed in the caudate, thalamus, globus pallidus, and ventral striatum (39).…”

Section: Tau Radiotracers In Cbsmentioning

confidence: 99%

Accumulation of Tau Protein, Metabolism and Perfusion—Application and Efficacy of Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) Imaging in the Examination of Progressive Supranuclear Palsy (PSP) and Corticobasal Syndrome (CBS)

et al. 2019

View full text Add to dashboard Cite

Neuroimaging in the context of examining atypical parkinsonian tauopathies is an evolving matter. Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) bring tools, which may be reasonable in supplementary examination, however cannot be interpreted as a gold standard for correct diagnosis. The review presents advantages and limitations of tau radiotracers in PET, metabolic PET and perfusion SPECT. The aim of this paper is to highlight the possibilities and boundaries in the supplementary examination of tauopathic parkinsonian syndromes.

show abstract

PBB3 binding in a patient with corticobasal syndrome

Cited by 7 publications

References 8 publications

Longitudinal changes in ¹⁸F‐THK5351 positron emission tomography in corticobasal syndrome

Longitudinal changes in ¹⁸F‐THK5351 positron emission tomography in corticobasal syndrome

Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework

Accumulation of Tau Protein, Metabolism and Perfusion—Application and Efficacy of Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) Imaging in the Examination of Progressive Supranuclear Palsy (PSP) and Corticobasal Syndrome (CBS)

Contact Info

Product

Resources

About

PBB3 binding in a patient with corticobasal syndrome

Cited by 7 publications

References 8 publications

Longitudinal changes in 18F‐THK5351 positron emission tomography in corticobasal syndrome

Longitudinal changes in 18F‐THK5351 positron emission tomography in corticobasal syndrome

Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework

Accumulation of Tau Protein, Metabolism and Perfusion—Application and Efficacy of Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) Imaging in the Examination of Progressive Supranuclear Palsy (PSP) and Corticobasal Syndrome (CBS)

Contact Info

Product

Resources

About

Longitudinal changes in ¹⁸F‐THK5351 positron emission tomography in corticobasal syndrome

Longitudinal changes in ¹⁸F‐THK5351 positron emission tomography in corticobasal syndrome